Elsevier

The Lancet

Volume 357, Issue 9263, 14 April 2001, Page 1141
The Lancet

Editorial
The tightening grip of big pharma

https://doi.org/10.1016/S0140-6736(00)04363-4Get rights and content

References (0)

Cited by (24)

  • The pharmaceutical industry as an informant

    2002, Lancet
    Citation Excerpt :

    Possibilities include inherent biases in trial design,15 for instance, by use of inappropriate comparator drugs,15,16 drug doses,16,17 or methods to assess outcomes.18,19 Occasionally, in attempts to ensure a positive bias, companies have threatened legal action to stop nominally independent researchers from publishing negative material.20–23 Moreover, researchers who communicate negative results have faced intimidation, efforts to discredit them professionally, and threats of legal action to recover the value of lost sales.24

View all citing articles on Scopus
View full text